Search Results

Mark G. Goldstein, MD, FACP is Board Certified in medical oncology and hematology.  Dr. Goldstein earned a B.S. in genetics at the University of Georgia, then his medical degree from St. George’s University.  He completed his residency at the University of Connecticut with two Commendations for Excellence in Patient Care, followed by a fellowship in…

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (V940-009) MOA: V940 is a lipid encapsulated mRNA based Individualized Neoantigen Therapy (INT) encoding neoantigens to induce specific T cells…

D702AC00001: A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer. (ARTEMIDE-Gastric01) MOA: Rilvegostomig is a bispecific antibody with an engineered triple-mutant Fc domain targeting PD-1 and TIGIT. Key Eligibility Criteria: Previously untreated, unresectable, locally advanced or…

Next-generation sequencing (NGS) results, treatment flexibility, and patient age must be carefully weighed to determine whether irinotecan liposome (Onivyde) plus oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (NALIRIFOX) is an appropriate first-line treatment for patients with metastatic pancreatic cancer, according to Dong Kim, MD. The regimen received FDA approval for this population in February 2024.1 “One of the…

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC) MOA: Fruquintinib is a highly selective and potent VEGFR inhibitor. Key Eligibility Criteria: Subjects must have confirmed mCRC Subjects with genetic aberrations are allowed No MSI-H and BRAF V600 Subjects must have received FOLFOX and BEV-based first…

A phase IIIb study to characterize the efficacy and safety of ADJUVANT ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (ADJUVANT WIDER) MOA: Aromatase inhibitor, CDK4/6 inhibitor, LHRH agonist Key Eligibility Criteria: Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive…